Angiogenesis inhibitors can be divided in 2 main groups according to their mechanism of action [3]: those that act directly on microvascular endothelial cells recruited by the tumor, such as ...

SU5416 is a small-molecule angiogenesis inhibitor that blocks the action of vascular endothelial growth factor receptor (VEGF-R) in endothelial cells, which is critical for new blood vessel formation.

After decades of work, Dr. Folkman and his team are now watching as clinical trials begin with two recently discovered angiogenesis inhibitors, endostatin and angiostatin. In this interview ...

The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

The Park Nicollet Institute is actively enrolling women with recurrent ovarian cancer for participation in a new clinical research study, called TRINOVA-2. Although there have been many ...

The process is regulated by a balance of endogenous angiogenesis stimulators (such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and the angiopoeitin family), ...

In this report, we will discuss some of the AACR data relating to angiogenesis in light of previous results from clinical trials, attempting to outline what has been achieved so far and what are ...